tenofovir has been researched along with Disease Exacerbation in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (27.08) | 29.6817 |
| 2010's | 30 (62.50) | 24.3611 |
| 2020's | 5 (10.42) | 2.80 |
| Authors | Studies |
|---|---|
| Abdool Karim, Q; Abdool Karim, SS; Garrett, NJ; McKinnon, LR; Molatlhegi, RP; Ngcapu, S; Ngcobo, S; Osman, F; Samsunder, N; Sivro, A | 1 |
| Chan, HL; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Chen, CH; Cheung, KS; Eguchi, Y; Enomoto, M; Furusyo, N; Hoang, J; Hsu, YC; Huang, CF; Huang, R; Huang, YT; Jang, TY; Kozuka, R; Kumada, T; Lee, DH; Li, J; Liu, C; Liu, L; Nguyen, MH; Ogawa, E; Peng, CY; Takahashi, H; Tanaka, Y; Toyoda, H; Trinh, H; Tsai, PC; Wong, C; Wong, GL; Wu, C; Xie, Q; Yang, HI; Yasuda, S; Yeh, ML; Yu, ML; Yuen, MF; Zhang, JQ; Zhao, C | 1 |
| Bogner, JR; Hilge, R; Schrader, SY; Seybold, U; Zeder, AJ | 1 |
| Balkus, J; Elharrar, V; Husnik, M; Jeenarain, N; Kabwigu, S; Levy, L; Livant, E; Mhlanga, F; Nair, G; Palanee-Phillips, T; Panchia, R; Pather, A; Patterson, K; Premrajh, A; Ramjee, G; Riddler, SA; Selepe, P; Siva, S; Tutshana, BO | 1 |
| Goorhuis, A; Kooij, KW; Post, FA; Prins, M; Reiss, P; van der Valk, M; van Zoest, RA; Vogt, L; Wit, FWNM | 1 |
| Chun, JM; Han, YS; Hur, K; Jang, SY; Kang, MK; Kweon, YO; Lee, HJ; Lee, HW; Lee, YR; Park, JG; Park, SY; Tak, WY | 1 |
| Jiang, XW; Li, LJ; Li, YT; Ye, JZ | 1 |
| Chan, HL; Lam, KL; Lui, GC; Szeto, CC; Tse, YK; Wong, GL; Wong, VW; Yip, TC | 1 |
| Ahn, SH; Han, KH; Hwang, SG; Kim, BK; Kim, DY; Kim, MN; Kim, SU; Kweon, YO; Lee, HA; Lee, HW; Lee, YR; Park, JY; Park, SY; Rim, KS; Seo, YS; Tak, WY; Um, SH | 1 |
| Belle, SH; Bzowej, NH; Chung, R; Khalili, M; Li, R; Smith, CI; Terrault, N; Tran, TT; Tsai, N | 1 |
| Wyles, DL | 1 |
| Asano, T; Fujiki, K; Furumoto, Y; Hayakawa, Y; Horiuchi, T; Kobayashi, K; Matsumoto, T; Matsuoka, M; Misumi, Y; Miura, N; Nozaka, T; Sakamoto, N | 1 |
| Acurcio, Fde A; Almeida, AM; Andrade, EI; Brandão, CM; Cherchiglia, ML; Oliveira, GL; Silva, AL | 1 |
| Abdool-Karim, Q; Abdool-Karim, SS; Garrett, NJ; Gray, C; Morris, L; Naicker, N; Naranbhai, V; Samsunder, N; Sibeko, S; Werner, L; Williamson, C | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Boettler, T; Thimme, R | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Li, Y; Lu, W; Tso, FY; Wood, C; Yuan, Z | 1 |
| Chen, J; Li, L; Qin, C; Ren, Y; Wan, Y; Wang, J; Wang, W; Wei, Q; Xu, J; Zhang, X | 1 |
| Badiou, S; Casanova, ML; Cournil, A; Cristol, JP; Peyriere, H; Reynes, J | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Estrella, MM; Machekano, R; Moosa, MR; Nachega, JB; Taljaard, JJ; Uthman, OA; Veldkamp, PJ; Zachor, H; Zeier, MD | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Arenas Ruiz Tapiador, J; Bonet Vidal, ML; Buti, M; Calleja, JL; Castro, Á; Crespo, J; Del Pino-Montes, J; Delgado Blanco, M; Diago, M; Fernández-Rodríguez, C; Fraga, E; García-Samaniego, J; González Diéguez, L; Morillas, R; Núñez, O; Pascasio, JM; Praga, M; Prieto, M; Rodríguez-Nóvoa, S; Romero-Gómez, M; Solá, R | 1 |
| Barreiro, P; Soriano, V; Tuma, P; Vispo, E | 1 |
| Buffet, C | 1 |
| Chetty, K; Connolly, JO; Edwards, SG; Hall, AM; Lapsley, M; O'Farrell, S; Unwin, RJ; Williams, IG | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Agarwala, R; Cheng, JT; Herlitz, LC; Mohan, S | 1 |
| Colquitt, J; Cooper, K; Harris, P; Jones, J; Shepherd, J | 1 |
| Beniowski, M; De Wit, S; Gatell, J; Kirk, O; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P; Sedlacek, D | 1 |
| Bonjoch, A; Clotet, B; del Rio, L; di Gregorio, S; Estany, C; Figueras, M; Gómez, G; Negredo, E; Perez-Alvarez, N; Puig, J; Rosales, J | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Camp, R; Connick, E; Daar, ES; Degruttola, V; Del Rio, C; Fiscus, SA; Hare, CB; Hogan, CM; Kallungal, B; Little, S; Macatangay, B; Markowitz, M; Morton, T; Sun, X; Tashima, KT | 1 |
| Lee, WM; Tujios, SR | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Bräu, N; Chang, MH; Fung, HB; Monteagudo-Chu, MO | 1 |
| Hu, KQ; Pan, CQ; Tsai, N | 1 |
| Bassetti, D; Bassetti, M; Ciravegna, BW; Di Biagio, A; Ferrazin, A; Rosso, R | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Bogner, JR; Crispin, A; Goebel, FD; Jülg, BD | 1 |
| Allen, TM; Bazmi, A; Fuller, DH; Fuller, JT; Haynes, JR; McMahon, CW; Mothe, B; Murphey-Corb, M; Rajakumar, PA; Shipley, T; Trichel, AM; Watkins, DI; Wu, MS | 1 |
| Berg, T; Feucht, HH; Hüppe, D; Möller, B; Sarrazin, C; Spengler, U; van Bömmel, F; Wiedenmann, B; Zöllner, B | 1 |
| de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA | 1 |
| Self, SG; Wick, D | 1 |
| Bischofberger, N; Brown, CR; Buckler-White, A; Endo, Y; Hirsch, V; Igarashi, T; Martin, MA; Plishka, R | 1 |
| Ansari, AA; Bostik, P; Brice, GT; June, CH; Mayne, AE; Mori, K; Villinger, F | 1 |
12 review(s) available for tenofovir and Disease Exacerbation
| Article | Year |
|---|---|
Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis.
Topics: Antibiotic Prophylaxis; Antiviral Agents; Coinfection; Disease Progression; Guanine; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Incidence; Interferons; Recurrence; Tenofovir; Treatment Outcome; Virus Activation | 2018 |
Antiretroviral Effects on HBV/HIV Co-infection and the Natural History of Liver Disease.
Topics: Anti-Retroviral Agents; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Prevalence; Prognosis; Risk Assessment; Survival Analysis; Tenofovir; Treatment Outcome | 2019 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Fatty Liver; Glucose Metabolism Disorders; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver; Liver Cirrhosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir | 2008 |
[Chronic hepatitis B: current therapy].
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Humans; Immunotherapy, Active; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Neoplasms; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome | 2008 |
Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Topics: Adenine; Alanine Transaminase; Antiviral Agents; Cost-Benefit Analysis; Disease Progression; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; Models, Economic; Organophosphonates; Quality of Life; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; United Kingdom | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
New advances in chronic hepatitis B.
Topics: Adenine; Antiviral Agents; Coinfection; Disease Progression; Drug Resistance, Viral; Female; Guanine; Guidelines as Topic; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Interferons; Liver Cirrhosis; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Tenofovir | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Topics: Adenine; Antiviral Agents; Asian People; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; Chronic Disease; Comorbidity; Disease Progression; HIV Infections; HIV-1; Humans; Kidney; Kidney Diseases; Kidney Failure, Chronic; Kidney Transplantation; Mice; Mice, Transgenic; Microcirculation; Organophosphonates; Tenofovir; Viral Proteins | 2007 |
6 trial(s) available for tenofovir and Disease Exacerbation
| Article | Year |
|---|---|
Pre-infection plasma cytokines and chemokines as predictors of HIV disease progression.
Topics: Adolescent; Adult; Anti-HIV Agents; Biomarkers; CD4-CD8 Ratio; Chemokines; Cohort Studies; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Immunity; Prognosis; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2022 |
HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial.
Topics: Adult; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; HIV Seropositivity; Humans; Placebos; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Young Adult | 2017 |
HIV disease progression in seroconvertors from the CAPRISA 004 tenofovir gel pre-exposure prophylaxis trial.
Topics: Adenine; Disease Progression; Female; Gels; HIV Infections; Humans; Organophosphonates; Placebos; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2015 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
The setpoint study (ACTG A5217): effect of immediate versus deferred antiretroviral therapy on virologic set point in recently HIV-1-infected individuals.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Organophosphonates; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2012 |
30 other study(ies) available for tenofovir and Disease Exacerbation
| Article | Year |
|---|---|
Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China.
Topics: Adult; Aftercare; Antiviral Agents; Carcinoma, Hepatocellular; China; Disease Progression; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; China; Cohort Studies; Disease Progression; Female; Guanine; Hepatitis B, Chronic; Hong Kong; Humans; International Cooperation; Japan; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Republic of Korea; Retrospective Studies; Taiwan; Tenofovir; Treatment Outcome; United States | 2020 |
Medium-grade proteinuria is a risk factor for incident markers of chronic kidney disease.
Topics: Adult; Age Factors; Anti-HIV Agents; Biomarkers; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Multivariate Analysis; Practice Guidelines as Topic; Prospective Studies; Proteinuria; Renal Insufficiency, Chronic; Tenofovir | 2020 |
Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.
Topics: Albuminuria; Anti-HIV Agents; Case-Control Studies; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Logistic Models; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Phosphates; Prevalence; Prospective Studies; Renal Insufficiency, Chronic; Risk Factors; Tenofovir | 2017 |
Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
Topics: Adult; Antiviral Agents; Disease Progression; DNA, Viral; Drug Resistance, Viral; End Stage Liver Disease; Female; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Republic of Korea; ROC Curve; Severity of Illness Index; Tenofovir; Treatment Outcome | 2018 |
Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Middle Aged; Registries; Renal Insufficiency, Chronic; Tenofovir; Treatment Outcome | 2018 |
A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Genotype; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Prognosis; Propensity Score; Republic of Korea; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Total Alanine Aminotransferase (ALT) Flares in Pregnant North American Women With Chronic Hepatitis B Infection: Results From a Prospective Observational Study.
Topics: Alanine Transaminase; Antiviral Agents; Asian People; Black People; Deprescriptions; Disease Progression; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Lamivudine; North America; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Tenofovir; Viral Load | 2019 |
A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
Topics: Aged; Alkynes; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoxazines; Chemoradiotherapy; Cisplatin; Cyclopropanes; Deglutition Disorders; Disease Progression; Drug Interactions; Emtricitabine; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fatal Outcome; Female; Fluorouracil; Gastrostomy; HIV Infections; Humans; Neoadjuvant Therapy; Neoplasm Staging; Renal Insufficiency; RNA, Viral; Tenofovir; Viral Load | 2020 |
Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
Topics: Adenine; Adult; Analysis of Variance; Antiviral Agents; Brazil; Cost-Benefit Analysis; Disease Progression; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Markov Chains; Organophosphonates; Tenofovir; Treatment Outcome | 2013 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
Antiviral Therapy in Hepatitis B Virus-Associated Liver Cirrhosis.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Guanine; Hepatitis B e Antigens; Hepatitis B, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD34; Bone Marrow; CD8-Positive T-Lymphocytes; Disease Models, Animal; Disease Progression; DNA, Viral; Gene Dosage; HIV Infections; HIV-1; Humans; Liver; Mice; Mice, Inbred NOD; Mice, Transgenic; Organophosphonates; Pilot Projects; RNA, Viral; Spleen; Tenofovir; Thymus Gland; Viral Load; Virus Replication | 2015 |
Mucosal Topical Microbicide Candidates Exert Influence on the Subsequent SIV Infection and Survival by Regulating SIV-Specific T-Cell Immune Responses.
Topics: Administration, Rectal; Animals; Anti-Infective Agents, Local; CD4-Positive T-Lymphocytes; Cyclohexanes; Disease Progression; Gene Expression Profiling; Humans; Immunity, Cellular; Macaca mulatta; Maraviroc; Mucous Membrane; Oligonucleotide Array Sequence Analysis; Peptides; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Survival Rate; Tenofovir; Triazoles; Viral Load | 2016 |
Long-Term Follow-Up of Proteinuria and Estimated Glomerular Filtration Rate in HIV-Infected Patients with Tubular Proteinuria.
Topics: Adult; Aged; Anti-HIV Agents; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Tubules; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Proteinuria; Tenofovir; Time Factors; Viral Load | 2015 |
Incidence of stage 3 chronic kidney disease and progression on tenofovir-based regimens.
Topics: Adult; Anti-HIV Agents; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; South Africa; Tenofovir | 2016 |
Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; Guanine; Hepatitis B, Chronic; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Nucleosides; Nucleotides; Retinol-Binding Proteins; Retrospective Studies; Spain; Tenofovir; Young Adult | 2016 |
Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis.
Topics: Acetylglucosaminidase; Adenine; Adult; Aged; Albuminuria; Anti-Retroviral Agents; Creatinine; Cross-Sectional Studies; Disease Progression; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Tubules, Proximal; Male; Middle Aged; Organophosphonates; Phosphates; Proteinuria; Retinol-Binding Proteins; Risk Factors; Sensitivity and Specificity; Tenofovir | 2009 |
The case: 41-year-old HIV patient with proteinuria and progressive renal dysfunction. Tenofovir toxicity.
Topics: Adenine; Adult; Anti-HIV Agents; Biopsy; Disease Progression; Humans; Kidney; Kidney Diseases; Kidney Tubules, Proximal; Male; Organophosphonates; Proteinuria; Tenofovir | 2010 |
Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Disease Progression; Epidemiologic Methods; Female; Glomerular Filtration Rate; HIV Seropositivity; HIV-1; Humans; Indinavir; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2010 |
High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study.
Topics: Absorptiometry, Photon; Adenine; Aged; Antiretroviral Therapy, Highly Active; Bone Density; Cohort Studies; Cross-Sectional Studies; Disease Progression; Female; HIV Infections; Humans; Longitudinal Studies; Male; Middle Aged; Organophosphonates; Osteoporosis; Prevalence; Radionuclide Imaging; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir | 2010 |
Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Dideoxynucleosides; Disease Progression; Female; Follow-Up Studies; Glomerular Filtration Rate; HIV Infections; Hospitals, Veterans; Humans; Incidence; Kidney; Male; Middle Aged; New York City; Organophosphonates; Outpatient Clinics, Hospital; Pilot Projects; Proportional Hazards Models; Renal Insufficiency, Chronic; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.
Topics: Acidosis, Lactic; Adenine; Adolescent; Antiretroviral Therapy, Highly Active; Carbamates; Diagnosis, Differential; Didanosine; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Female; Furans; Guillain-Barre Syndrome; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Organophosphonates; Organophosphorus Compounds; Risk Assessment; Severity of Illness Index; Stavudine; Sulfonamides; Tenofovir | 2003 |
Progression of renal impairment under therapy with tenofovir.
Topics: Adenine; Anti-HIV Agents; Case-Control Studies; Disease Progression; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2005 |
Case study: an active, 24-year-old woman positive for HIV.
Topics: Adenine; Adult; Anti-Retroviral Agents; Deoxycytidine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Organophosphonates; Ritonavir; Tenofovir | 2006 |
DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cell Proliferation; Disease Progression; Epitopes, T-Lymphocyte; Gene Products, gag; Gene Products, tat; Immunotherapy, Active; Macaca mulatta; Organophosphonates; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Statistics as Topic; Tenofovir; Vaccines, DNA; Viremia; Withholding Treatment | 2006 |
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy.
Topics: Adenine; Adult; Disease Progression; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Virus Replication | 2006 |
Early HIV infection in vivo: branching-process model for studying timing of immune responses and drug therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Computer Simulation; Disease Progression; HIV; HIV Infections; Humans; Macaca; Macrophages; Models, Immunological; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Soman; Stochastic Processes; Tenofovir; Time Factors; Viral Load | 2000 |
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Chimera; Digestive System; Disease Progression; Drug Resistance, Microbial; HIV Infections; HIV-1; Lentivirus Infections; Lymphoid Tissue; Macaca mulatta; Macrophages; Organ Specificity; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Virus Replication | 2001 |
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Topics: Adenine; Animals; Antibodies, Viral; Antiviral Agents; Blood Transfusion, Autologous; CD4-Positive T-Lymphocytes; Combined Modality Therapy; Disease Progression; DNA, Viral; Immunotherapy, Adoptive; Leukocytes, Mononuclear; Macaca mulatta; Neutralization Tests; Organophosphonates; Organophosphorus Compounds; Proviruses; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Tenofovir; Viral Load | 2002 |